CG Oncology, Inc. Common stock (CGON) - Total Assets
Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) holds total assets worth $791.59 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of CG Oncology, Inc. Common stock for net asset value and shareholders' equity analysis.
CG Oncology, Inc. Common stock - Total Assets Trend (2021–2025)
This chart illustrates how CG Oncology, Inc. Common stock's total assets have evolved over time, based on quarterly financial data.
CG Oncology, Inc. Common stock - Asset Composition Analysis
Current Asset Composition (December 2025)
CG Oncology, Inc. Common stock's total assets of $791.59 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.1% |
| Accounts Receivable | $688.00K | 0.1% |
| Inventory | $1.56 Million | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $575.00K | 0.1% |
| Goodwill | $10.30 Million | 1.3% |
Asset Composition Trend (2021–2025)
This chart illustrates how CG Oncology, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CG Oncology, Inc. Common stock (CGON) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CG Oncology, Inc. Common stock's current assets represent 95.9% of total assets in 2025, a decrease from 99.5% in 2021.
- Cash Position: Cash and equivalents constituted 4.1% of total assets in 2025, down from 91.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 1.3% of total assets.
CG Oncology, Inc. Common stock Competitors by Total Assets
Key competitors of CG Oncology, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
CG Oncology, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.63 | 35.30 | 9.54 |
| Quick Ratio | 24.58 | 35.30 | 9.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $728.64 Million | $732.84 Million | $131.78 Million |
CG Oncology, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between CG Oncology, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.57 |
| Latest Market Cap to Assets Ratio | 6.60 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | $791.59 Million |
| Market Capitalization | $5.23 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values CG Oncology, Inc. Common stock's assets at a significant premium (6.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: CG Oncology, Inc. Common stock's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual total assets of CG Oncology, Inc. Common stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $791.59 Million | +4.87% |
| 2024-12-31 | $754.80 Million | +278.72% |
| 2023-12-31 | $199.30 Million | +34.89% |
| 2022-12-31 | $147.75 Million | +151.73% |
| 2021-12-31 | $58.69 Million | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more